



Digestive Diseases Research Seminar Series

Presented by

Yale School of Medicine, Department of Internal Medicine, Section of Digestive Diseases

“A Novel Treatment Approach for NASH”

Gerald Shulman, MD, PhD, FACP, MACE
Yale School of Medicine

Date: February 14, 2017

Location: TAC S-247

Time: 5:00pm-6:00pm

Host: Dr. Mario Strazzabosco

There is no corporate support for this activity

This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

Yale Medical School Faculty, Fellows, & Staff
Local GI Physicians

NEEDS ASSESSMENT

This lecture will address the clinical gap in the understanding of the pathogenesis and treatment of NAFLD and NASH (Shulman, NEJM 2016).

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Understand the role of ectopic lipid in the pathogenesis of type 2 diabetes and the metabolic syndrome.
2. Understand the molecular mechanisms of lipid-induced liver and muscle insulin resistance.
3. Understand the potential efficacy of liver-targeted mitochondrial uncoupling for the treatment of NASH.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Gerald Shulman – Merck (Scientific Advisory Board)
Novartis (Scientific Advisory Board)

Mario Strazzabosco

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.